Vertex Pharmaceuticals
VRTX
$450.46
+1.24%
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing small-molecule drugs and advanced therapies for serious diseases. It is the undisputed market leader in cystic fibrosis (CF) treatments, with its portfolio including Kalydeco, Orkambi, Symdeko, and the blockbuster Trikafta/Kaftrio, which set the global standard of care. The current investor narrative is dominated by the company's successful diversification beyond CF, highlighted by the recent Phase 3 win for its kidney disease drug and the expansion of its gene-editing therapy, Casgevy, into pediatric populations for rare blood disorders, positioning Vertex for its next major wave of growth.…
VRTX
Vertex Pharmaceuticals
$450.46
Related headlines
VRTX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $585.60 and implied upside of +30.0% versus the current price.
Average Target
$585.60
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$360 - $586
Analyst target range
Analyst sentiment is overwhelmingly bullish, with 12 firms providing coverage and recent institutional ratings showing a clear pattern of Buy or Overweight actions, including an upgrade from Maxim Group in March 2026. The consensus recommendation is a Buy, with an average target price implied by estimated EPS of $33.12 and a forward PE of 20.72x, yielding a price target of approximately $686, representing a substantial 54% upside from the current price of $444.93. The target range is wide, reflecting the binary nature of biotech outcomes; the high target (EPS $36.28) assumes flawless commercial execution and pipeline success, while the low target (EPS $31.65) likely factors in competitive or reimbursement risks. The recent flurry of analyst activity in March 2026, coinciding with positive clinical trial data, reinforces strong near-term conviction, though the wide spread between high and low estimates underscores the inherent uncertainty in valuing future pipeline contributions.
Bulls vs Bears: VRTX Investment Factors
The evidence presents a classic battle between strong fundamentals and weak technicals. The bull case is anchored in Vertex's exceptional profitability, fortress balance sheet, and successful pipeline diversification, which analysts believe justifies a 54% upside. The bear case is driven by severe price underperformance, decelerating core revenue growth, and a valuation that appears stretched relative to recent history. Currently, the fundamental bull case appears stronger, given the concrete financial strength and pipeline catalysts. However, the single most important tension is whether the market will reward Vertex's pipeline success and earnings power before the technical downtrend breaks, or if continued growth deceleration and high valuation will keep the stock range-bound. The resolution hinges on upcoming commercial execution for Casgevy and the kidney drug versus the next quarterly revenue growth figure.
Bullish
- Robust Profitability and Cash Flow: Vertex generates exceptional earnings with a net income of $1.19B in Q4 2025 and industry-leading gross margins of 85.6%. Its trailing twelve-month free cash flow of $3.19B provides a massive war chest for R&D and business development without diluting shareholders.
- Strong Analyst Conviction and Upside: Analyst consensus is a Buy with an average target price of ~$686, implying a 54% upside from the current price of $444.93. This bullish sentiment is reinforced by recent upgrades following positive Phase 3 data for its kidney disease drug.
- Fortress Balance Sheet: The company has a formidable financial position with $5.09B in cash, a low debt-to-equity ratio of 0.21, and a strong current ratio of 2.90. This provides significant resilience and strategic optionality in any market environment.
- Successful Pipeline Diversification: Recent Phase 3 success in kidney disease and the pediatric expansion of gene therapy Casgevy (with 100% efficacy in trials) demonstrate tangible progress in reducing reliance on the CF franchise, de-risking the long-term growth narrative.
Bearish
- Severe Technical Downtrend and Underperformance: VRTX is down 3.29% over the past year, underperforming the S&P 500 by a staggering 26.15%. Trading near 30% of its 52-week range ($362.50-$507.92) indicates persistent selling pressure and a lack of positive momentum.
- Revenue Growth Deceleration: Q4 2025 revenue growth of 10.82% YoY, while robust, shows a sequential slowdown from higher rates in prior quarters. This highlights the challenge of sustaining high growth rates from the mature CF franchise, which still dominates revenue.
- High Historical Valuation Premium: The trailing P/E of 29.32x is elevated compared to the stock's own recent historical averages (e.g., 24.16x at Q4 2025). This premium valuation leaves little room for error and makes the stock vulnerable to multiple compression if growth disappoints.
- CF Franchise Dependency and Pipeline Execution Risk: Despite diversification efforts, the CF portfolio (e.g., Trikafta/Kaftrio at $2.57B in Q4) remains the overwhelming profit driver. The future valuation hinges entirely on successful commercial execution and regulatory approval for new pipeline assets like the kidney drug and Casgevy.
VRTX Technical Analysis
The stock is in a pronounced downtrend and consolidation phase, having declined 3.29% over the past year, which starkly contrasts with the S&P 500's 22.86% gain, resulting in a severe 26.15% relative underperformance. Currently trading at $444.93, the price sits at approximately 30% of its 52-week range ($362.50 to $507.92), indicating it is much closer to its annual lows than its highs, which suggests either a deep value opportunity or a stock facing significant fundamental headwinds. Recent momentum remains weak, with the stock down 1.80% over the past month and 5.20% over the past three months, confirming the bearish trend is intact and showing no signs of reversal. The stock exhibits low market-correlated volatility with a beta of 0.31, but its own price action has been volatile, evidenced by a maximum drawdown of -23.56% over the provided period. Key technical levels are clearly defined, with immediate support at the 52-week low of $362.50 and resistance at the 52-week high of $507.92; a sustained break below support could trigger a new leg down, while a move above resistance would signal a major trend reversal, though current momentum does not favor the latter.
Beta
0.31
0.31x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$363-$508
Price range past year
Annual Return
-1.1%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | +3.1% | +2.1% |
| 3m | -2.6% | +12.5% |
| 6m | +0.2% | +12.4% |
| 1y | -1.1% | +26.4% |
| ytd | -0.4% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Revenue growth remains robust but has shown some sequential deceleration; Q4 2025 revenue was $3.23 billion, representing a 10.82% year-over-year increase, though this marks a slowdown from the higher growth rates seen in prior quarters of 2025. The cystic fibrosis franchise, led by Trikafta/Kaftrio which contributed $2.57 billion in the period, continues to be the primary growth engine, while newer products like Alyftrek ($380 million) and the nascent launch of Casgevy provide diversification. Profitability is exceptionally strong, with the company reporting net income of $1.19 billion in Q4 2025 and maintaining industry-leading gross margins of 85.56%; operating margins have also been healthy at 39.43% (trailing), demonstrating the company's ability to convert dominant market share into substantial earnings. The balance sheet is fortress-like, featuring a massive cash position of $5.09 billion, a low debt-to-equity ratio of 0.21, and a strong current ratio of 2.90, indicating ample liquidity. The company is a prolific cash generator, with trailing twelve-month free cash flow of $3.19 billion, providing internal funding for R&D and business development without reliance on external capital, further supported by a high return on equity of 21.18%.
Quarterly Revenue
$3.2B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Given the company's substantial profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 29.32x, while the forward PE is significantly lower at 20.72x, indicating the market expects meaningful earnings growth over the next twelve months. Compared to the broader biotechnology sector, Vertex's trailing PE of 29.32x trades at a premium; this premium is arguably justified by the company's unique profile as a profitable, cash-generating market leader with a de-risked commercial portfolio, unlike many pre-profit biotech peers. Historically, the stock's current trailing PE of 29.32x is above its own multi-year average observable in the data (e.g., 24.16x at Q4 2025, 23.11x at Q3 2025), suggesting the stock is trading at the higher end of its historical valuation range, which prices in successful execution on its new pipeline catalysts like the kidney disease drug and Casgevy expansion.
PE
29.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~195x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Vertex's primary financial risk is its heavy reliance on the mature Cystic Fibrosis franchise, which contributed $2.57B of its $3.23B Q4 revenue. While growth remains positive at 10.82% YoY, this deceleration trend poses a risk to the high valuation multiples if it persists. The company's substantial profitability (39.4% operating margin) and $3.19B in annual FCF mitigate cash burn risk, but the high trailing P/E of 29.32x creates valuation compression risk if earnings growth fails to meet elevated expectations.
Market & Competitive Risks: The stock trades at a premium to its own historical P/E, making it vulnerable to sector-wide de-rating of growth stocks, especially given its low beta of 0.31 which hasn't protected it from a 26% relative underperformance vs. the S&P 500. Competitive risks are moderate but increasing as Vertex moves beyond its monopolistic CF franchise into competitive areas like gene editing (Casgevy) and kidney disease. Regulatory and reimbursement hurdles for these new, expensive therapies represent a significant external threat to the pipeline's commercial potential.
Worst-Case Scenario: The worst-case scenario involves a combination of faster-than-expected CF revenue decline, pipeline setbacks (e.g., regulatory delays for the kidney drug), and a broader biotech valuation contraction. This could trigger a re-rating to the lower end of its historical P/E range alongside earnings downgrades. The realistic downside is to the 52-week low of $362.50, representing a potential loss of approximately -18.5% from the current price of $444.93. A breach of this support could see the stock test levels implied by the analyst low EPS target of $31.65, which at a 20x multiple suggests a price near $633, though this still represents upside, highlighting the skewed risk/reward to the upside based on current targets.
